ALNY Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of -22.27% compared to Alnylam Pharmaceuticals's net margin of 16.61%. Alnylam Pharmaceuticals's return on equity of -- beat Gilead Sciences's return on equity of 0.64%.

Alnylam Pharmaceuticals has a consensus price target of $298.97, signalling upside risk potential of 24.29%. On the other hand Gilead Sciences has an analysts' consensus of $98.88 which suggests that it could grow by 10.93%. Given that Alnylam Pharmaceuticals has higher upside potential than Gilead Sciences, analysts believe Alnylam Pharmaceuticals is more attractive than Gilead Sciences.

Alnylam Pharmaceuticals has a beta of 0.342, which suggesting that the stock is 65.841% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.179, suggesting its less volatile than the S&P 500 by 82.12%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.46% to investors and pays a quarterly dividend of $0.77 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Gilead Sciences pays out 67.24% of its earnings as a dividend. Gilead Sciences's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alnylam Pharmaceuticals quarterly revenues are $500.9M, which are smaller than Gilead Sciences quarterly revenues of $7.5B. Alnylam Pharmaceuticals's net income of -$111.6M is lower than Gilead Sciences's net income of $1.3B. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 990.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 14.56x versus 3.94x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -22.27% compared to Alnylam Pharmaceuticals's net margin of 25.23%. Alnylam Pharmaceuticals's return on equity of -- beat Pfizer's return on equity of 4.63%.

Alnylam Pharmaceuticals has a consensus price target of $298.97, signalling upside risk potential of 24.29%. On the other hand Pfizer has an analysts' consensus of $31.78 which suggests that it could grow by 18.3%. Given that Alnylam Pharmaceuticals has higher upside potential than Pfizer, analysts believe Alnylam Pharmaceuticals is more attractive than Pfizer.

Alnylam Pharmaceuticals has a beta of 0.342, which suggesting that the stock is 65.841% less volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.26% to investors and pays a quarterly dividend of $0.42 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $500.9M, which are smaller than Pfizer quarterly revenues of $17.7B. Alnylam Pharmaceuticals's net income of -$111.6M is lower than Pfizer's net income of $4.5B. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 14.56x versus 2.57x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -22.27% compared to Alnylam Pharmaceuticals's net margin of 36.03%. Alnylam Pharmaceuticals's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Alnylam Pharmaceuticals has a consensus price target of $298.97, signalling upside risk potential of 24.29%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,045.03 which suggests that it could grow by 42.46%. Given that Regeneron Pharmaceuticals has higher upside potential than Alnylam Pharmaceuticals, analysts believe Regeneron Pharmaceuticals is more attractive than Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.342, which suggesting that the stock is 65.841% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $500.9M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Alnylam Pharmaceuticals's net income of -$111.6M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 18.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 14.56x versus 6.10x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -22.27% compared to Alnylam Pharmaceuticals's net margin of 7.2%. Alnylam Pharmaceuticals's return on equity of -- beat Sarepta Therapeutics's return on equity of 12.48%.

Alnylam Pharmaceuticals has a consensus price target of $298.97, signalling upside risk potential of 24.29%. On the other hand Sarepta Therapeutics has an analysts' consensus of $184.91 which suggests that it could grow by 46.63%. Given that Sarepta Therapeutics has higher upside potential than Alnylam Pharmaceuticals, analysts believe Sarepta Therapeutics is more attractive than Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.342, which suggesting that the stock is 65.841% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.770, suggesting its less volatile than the S&P 500 by 22.964%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $500.9M, which are larger than Sarepta Therapeutics quarterly revenues of $467.2M. Alnylam Pharmaceuticals's net income of -$111.6M is lower than Sarepta Therapeutics's net income of $33.6M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 81.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 14.56x versus 7.75x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.